Using signatures developed to predict pan-cancer response to immunotherapy (32), we found angiogenesis, epithelial-mesenchymal transition (EMT), and protumor cytokines to be the most significantly enriched pathways in high compared with low-NOTCH1-expressing tumors (Figure 4A). Here, NOTCH1 is linked to cancer.